185,732 Shares in Kenvue Inc. $KVUE Purchased by Ieq Capital LLC

Ieq Capital LLC acquired a new position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 185,732 shares of the company's stock, valued at approximately $3,549,000.

A number of other institutional investors have also recently bought and sold shares of the stock. CoreCap Advisors LLC raised its stake in Kenvue by 64.9% during the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company's stock worth $29,000 after purchasing an additional 591 shares during the period. Montag A & Associates Inc. increased its holdings in shares of Kenvue by 6.3% during the 1st quarter. Montag A & Associates Inc. now owns 10,156 shares of the company's stock worth $175,000 after buying an additional 600 shares during the last quarter. Cornerstone Wealth Group LLC increased its holdings in shares of Kenvue by 5.9% during the 1st quarter. Cornerstone Wealth Group LLC now owns 10,810 shares of the company's stock worth $187,000 after buying an additional 606 shares during the last quarter. Physician Wealth Advisors Inc. raised its position in shares of Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company's stock worth $26,000 after buying an additional 618 shares during the period. Finally, Mill Creek Capital Advisors LLC boosted its holdings in Kenvue by 0.6% in the fourth quarter. Mill Creek Capital Advisors LLC now owns 124,213 shares of the company's stock valued at $2,143,000 after acquiring an additional 701 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Stock Performance

Shares of NYSE:KVUE opened at $19.41 on Tuesday. The business's 50-day simple moving average is $19.08 and its 200 day simple moving average is $18.21. The company has a market cap of $37.27 billion, a P/E ratio of 22.30, a PEG ratio of 1.36 and a beta of 0.47. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.71 and a current ratio of 1.01. Kenvue Inc. has a one year low of $14.02 and a one year high of $21.63.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.31 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by ($0.01). Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The company had revenue of $3.96 billion during the quarter, compared to analysts' expectations of $3.97 billion. During the same quarter in the prior year, the company earned $0.29 EPS. The firm's revenue was up 3.0% compared to the same quarter last year. On average, sell-side analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, August 26th. Stockholders of record on Wednesday, August 12th will be paid a $0.21 dividend. This represents a $0.84 annualized dividend and a dividend yield of 4.3%. This is a boost from Kenvue's previous quarterly dividend of $0.21. The ex-dividend date is Wednesday, August 12th. Kenvue's payout ratio is currently 96.55%.

Wall Street Analyst Weigh In

KVUE has been the subject of a number of research reports. Wall Street Zen cut Kenvue from a "buy" rating to a "hold" rating in a report on Saturday, August 8th. Barclays lifted their price target on shares of Kenvue from $18.00 to $19.00 and gave the company an "equal weight" rating in a research report on Tuesday, July 21st. Weiss Ratings raised shares of Kenvue from a "hold (c-)" rating to a "hold (c)" rating in a research report on Monday, June 15th. Zacks Research lowered shares of Kenvue from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 7th. Finally, UBS Group cut their target price on shares of Kenvue from $20.00 to $19.00 and set a "neutral" rating on the stock in a research note on Tuesday, August 11th. Three research analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the stock. According to MarketBeat, Kenvue presently has a consensus rating of "Hold" and an average target price of $19.27.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source